Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
FR0012333284
Tue, 29.04.2025
ABIVAX
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment [ … ]
Tue, 22.04.2025
ABIVAX
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, France
Phase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025
PARIS, France – Apr [ … ]
Tue, 22.04.2025
ABIVAX
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025
PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical [ … ]
Wed, 26.03.2025
ABIVAX
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to sta [ … ]
Mon, 24.03.2025
ABIVAX
Abivax Announces Full Year 2024 Financial Results
Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025
Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025
PAR [ … ]
Fri, 21.02.2025
ABIVAX
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax’s Pivotal ABTECT Phase 3 Trial
PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” [ … ]
Tue, 28.01.2025
ABIVAX
Abivax Publishes 2025 Financial Calendar
PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communica [ … ]
Thu, 23.01.2025
ABIVAX
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
PARIS, France – January 23, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing [ … ]
Thu, 09.01.2025
ABIVAX
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion expected in Q2 2025.
Top-line results for the 8-week induction trial anticipated i [ … ]